Global Klebsiella Pneumoniae Infections Treatment Market Promising Drugs R&D Opening New Opporunities, finds TMR

A new intelligence study by Transparency Market Research, titled “Klebsiella Pneumoniae Infections Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014–2020,” presents a detailed overview of the market. Analyzing the market for development trends of the past, the report provides pin-point analysis of changing competitive dynamics and aims to help the existing market players to understand the key product segments. The report estimates the state of the market over the years from 2014 to 2020. The report also segments the market into key geographical regions to analyze the status of the global and domestic players besides profiling of some of the leading players in the global market for klebsiella pneumoniae infections treatment.

Read Full Report: http://www.transparencymarketresearch.com/klebsiella-pneumoniae-infections-treatment.html

The Centers for Disease Control and Prevention (CDC) states that over 2 million patients suffer from nosocomial infections annually. Out of these, an estimated 100,000 people succumb due to these diseases. Klebsiella pneumonia contributes to 8% of overall nosocomial infections and as a result provides stability to the global market for klebsiella pneumonia infections treatment market. Several antibiotics are currently being used to treat several infectious diseases caused by pathogenic microbes. However, many such medicines are becoming ineffective as the pathogenic microorganisms are growing resistant by evolving themselves into multi drug resistant (MDR) strains. As a result, there is a growing need for medicines that can treat the infectious strains of klebsiella genus.

The report observes that widespread research activities are ongoing to find better therapies for klebsiella pneumonia infections, although modest success has been achieved till date. A few promising drugs and procedures for treatment that are in various stages of development and are expected to bring progress in the field include CB-618, RX-04, CB-027, SGX-942, SM-295291, SM-369926, NAB-741, IBN-1, NAB-7061, and PMBN-fMLF.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2859

This report is aimed at providing a comprehensive analysis of several important factors that are primed to affect the future of klebsiella pneumoniae infections treatment market, both at the global and regional level. The factors includes the market growth drivers, restraints, market structure, market projections for upcoming years. Porter’s five force model analysis has also been included.

Some of the prominent players in the global klebsiella pneumoniae infection treatment market with new drugs in the pipeline include Arsanis Biosciences GmbH, Cubist Pharmaceuticals, Inc., Cantab Biopharmaceuticals Ltd., FOB Synthesis, Inc., Melinta Therapeutics, Inc., Northern Antibiotics Oy, Phico Therapeutics Ltd., Dainippon Sumitomo Pharma Co. Ltd., Procarta Biosystems Ltd., Pfizer, Inc., Soligenix, Inc., Rib-X Pharmaceuticals, Inc., Trana Discovery, Inc., and Tetraphase pharmaceuticals, Inc.

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.